1. Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, editors. SEER Cancer Statistics Review, 1975-2012. Bethesda, MD: National Cancer Institute;Updated on Apr 2015.
http://seer.cancer.gov/csr/1975_2012.
2. Manser R, Lethaby A, editors. Screening for lung cancer. Cochrane database of systematic reviews 2013, Issue 6. Art. No.:CD001991. John Wiley & Sons, Ltd;2013. p. 3–10. DOI:
10.1002/14651858.CD001991.pub3.
3. Tas F, Aydiner A, Topuz E, Yasasever V, Karadeniz A, Saip P. Utility of the serum tumor markers: CYFRA 21.1, carcinoembryonic antigen (CEA), and squamous cell carcinoma antigen (SCC) in squamous cell lung cancer. J Exp Clin Cancer Res. 2000; 19:477–481. PMID:
11277326.
4. Brower V. Biomarker studies abound for early detection of lung cancer. J Natl Cancer Inst. 2009; 101:11–13. PMID:
19116384.
5. Hellström I, Raycraft J, Hayden-Ledbetter M, Ledbetter JA, Schummer M, McIntosh M, et al. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res. 2003; 63:3695–3700. PMID:
12839961.
6. Kong SY, Han MH, Yoo HJ, Hwang JH, Lim MC, Seo SS, et al. Serum HE4 level is an independent prognostic factor in epithelial ovarian cancer. Ann Surg Oncol. 2012; 19:1707–1712. PMID:
21833668.
7. Galgano MT, Hampton GM, Frierson HF Jr. Comprehensive analysis of HE4 expression in normal and malignant human tissues. Mod Pathol. 2006; 19:847–853. PMID:
16607372.
8. Iwahori K, Suzuki H, Kishi Y, Fujii Y, Uehara R, Okamoto N, et al. Serum HE4 as a diagnostic and prognostic marker for lung cancer. Tumour Biol. 2012; 33:1141–1149. PMID:
22373583.
9. Sobin LH, Gospodarowicz MK, editors. TNM classification of malignant tumors. 7th ed. Oxford, UK: Wiley-Blackwell;2009.
10. Galateau-Salle F, Churg A, Roggli V, Travis WD. World Health Organization Committee for Tumors of the Pleura. The 2015 World Health Organization classification of tumors of the pleura: Advances since the 2004 classification. J Thorac Oncol. 2016; 11:142–154. PMID:
26811225.
11. Thompson RC, Ohlsson K. Isolation, properties, and complete amino acid sequence of human secretory leukocyte protease inhibitor, a potent inhibitor of leukocyte elastase. Proc Natl Acad Sci U S A. 1986; 83:6692–6696. PMID:
3462719.
12. Wiedow O, Schröder JM, Gregory H, Young JA, Christophers E. Elafin: an elastase-specific inhibitor of human skin. Purification, characterization, and complete amino acid sequence. J Biol Chem. 1990; 265:14791–14795. PMID:
2394696.
13. Devoogdt N, Revets H, Ghassabeh GH, De Baetselier P. Secretory leukocyte protease inhibitor in cancer development. Ann N Y Acad Sci. 2004; 1028:380–389. PMID:
15650263.
14. Zhang M, Zou Z, Maass N, Sager R. Differential expression of elafin in human normal mammary epithelial cells and carcinomas is regulated at the transcriptional level. Cancer Res. 1995; 55:2537–2541. PMID:
7780965.
15. Liu W, Yang J, Chi PD, Zheng X, Dai SQ, Chen H, et al. Evaluating the clinical significance of serum HE4 levels in lung cancer and pulmonary tuberculosis. Int J Tuberc Lung Dis. 2013; 17:1346–1353. PMID:
24025389.
16. Nagy B Jr, Krasznai ZT, Balla H, Csobán M, Antal-Szalmás P, Hernádi Z, et al. Elevated human epididymis protein 4 concentrations in chronic kidney disease. Ann Clin Biochem. 2012; 49:377–380. PMID:
22688735.
17. Tang QF, Zhou ZW, Ji HB, Pan WH, Sun MZ. Value of serum marker HE4 in pulmonary carcinoma diagnosis. Int J Clin Exp Med. 2015; 8:19014–19021. PMID:
26770527.
18. Escudero JM, Auge JM, Filella X, Torne A, Pahisa J, Molina R. Comparison of serum human epididymis protein 4 with cancer antigen 125 as a tumor marker in patients with malignant and nonmalignant diseases. Clin Chem. 2011; 57:1534–1544. PMID:
21933899.
19. Ferraro S, Braga F, Lanzoni M, Boracchi P, Biganzoli EM, Panteghini M. Serum human epididymis protein 4 vs carbohydrate antigen 125 for ovarian cancer diagnosis: a systematic review. J Clin Pathol. 2013; 66:273–281. PMID:
23426716.